首页 > 最新文献

Kidney cancer journal : official journal of the Kidney Cancer Association最新文献

英文 中文
Robotic-assisted cytoreductive partial nephrectomy for metastatic sarcomatoid renal cell carcinoma following dramatic response to combination immunotherapy in a young female. 机器人辅助的细胞减少性部分肾切除术治疗转移性肉瘤样肾细胞癌，在联合免疫治疗后显着反应。
Kidney cancer journal : official journal of the Kidney Cancer Association
Pub Date : 2023-06-01
Yasin Bhanji, Ezra Baraban, Brian Antonucci, Yasser Ged, Nirmish Singla

Novel immune checkpoint inhibitors (ICI) have yielded remarkable response rates in metastatic renal cell carcinoma (RCC), including sarcomatoid RCC (sRCC). Here, we show the feasibility and efficacy of robotic-assisted cytoreductive partial nephrectomy (cPN) following a remarkable response to combination ICI for metastatic sRCC in a young female. A female in her late 40s presented with poor-risk, metastatic sRCC emanating from a 6.5 cm left renal mass including pulmonary involvement, retroperitoneal lymphadenopathy, and a scalp metastasis. She received 4 cycles of combination ipilimumab and nivolumab followed by maintenance nivolumab with a remarkable and durable response. Given the apparent downstaging of her primary tumor, a robotic cPN was pursued for residual ypT1aNoRo sRCC and found to be both feasible and safe with exceptional perioperative outcomes. She has since done well clinically and oncologically. Our unique case of metastatic sRCC in a young female highlights several aspects pertinent to the contemporary management of metastatic RCC including the role for cytoreductive nephrectomy in selected patients, the safety and feasibility of a nephron-sparing and minimally-invasive approach to cytoreduction after downstaging with ICI, and remarkable sensitivity of sRCC-a classically aggressive entity-to ICI.

新型免疫检查点抑制剂(ICI)在转移性肾细胞癌(RCC)，包括肉瘤样RCC (sRCC)中产生了显著的应答率。在这里，我们展示了机器人辅助的细胞减少性部分肾切除术(cPN)的可行性和有效性，在联合ICI治疗转移性sRCC的年轻女性中取得了显著的疗效。女性，40多岁，低风险，转移性sRCC来自6.5厘米的左肾肿块，包括肺部累及，腹膜后淋巴结病和头皮转移。她接受了4个周期的伊匹单抗和纳武单抗联合治疗，随后是维持纳武单抗，疗效显著且持久。鉴于其原发肿瘤的明显分期下降，我们对残留的ypT1aNoRo sRCC进行了机器人cPN治疗，发现该方法既可行又安全，并具有特殊的围手术期预后。从那以后，她的临床和肿瘤治疗都做得很好。我们一名年轻女性转移性肾细胞癌的独特病例突出了当代转移性肾细胞癌治疗的几个方面，包括在选择的患者中进行细胞减少性肾切除术的作用，保留肾细胞和微创方法在ICI降期后减少细胞的安全性和可行性，以及sRCC(典型的侵袭性实体)对ICI的显著敏感性。
{"title":"Robotic-assisted cytoreductive partial nephrectomy for metastatic sarcomatoid renal cell carcinoma following dramatic response to combination immunotherapy in a young female.","authors":"Yasin Bhanji, Ezra Baraban, Brian Antonucci, Yasser Ged, Nirmish Singla","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Novel immune checkpoint inhibitors (ICI) have yielded remarkable response rates in metastatic renal cell carcinoma (RCC), including sarcomatoid RCC (sRCC). Here, we show the feasibility and efficacy of robotic-assisted cytoreductive partial nephrectomy (cPN) following a remarkable response to combination ICI for metastatic sRCC in a young female. A female in her late 40s presented with poor-risk, metastatic sRCC emanating from a 6.5 cm left renal mass including pulmonary involvement, retroperitoneal lymphadenopathy, and a scalp metastasis. She received 4 cycles of combination ipilimumab and nivolumab followed by maintenance nivolumab with a remarkable and durable response. Given the apparent downstaging of her primary tumor, a robotic cPN was pursued for residual ypT1aNoRo sRCC and found to be both feasible and safe with exceptional perioperative outcomes. She has since done well clinically and oncologically. Our unique case of metastatic sRCC in a young female highlights several aspects pertinent to the contemporary management of metastatic RCC including the role for cytoreductive nephrectomy in selected patients, the safety and feasibility of a nephron-sparing and minimally-invasive approach to cytoreduction after downstaging with ICI, and remarkable sensitivity of sRCC-a classically aggressive entity-to ICI.</p>","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"21 2","pages":"15-18"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10656055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138048966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimal Duration of Therapy in Metastatic RCC: Exploring Treatment-Free Survival with Checkpoint Inhibitors 转移性RCC的最佳治疗时间:探索检查点抑制剂的无治疗生存期
Kidney cancer journal : official journal of the Kidney Cancer Association
Pub Date : 2022-09-29 DOI: 10.52733/kcj20n3-a1
Grayce Selig, C. Hoimes, Joe Bible, D. George, M. Harrison
The optimal duration of treatment for patients with metastatic renal cell carcinoma (mRCC) on dual immune checkpoint inhibitor (ICI) therapy remains unknown. However, there is evolving evidence that a portion of patients who achieve a complete or partial response will have a durable response, even after therapy discontinuation, leading to prolonged treatment-free survival (TFS). TFS with dual ICI is a phenomenon not seen with targeted agents and has the potential to improve patient reported outcomes and quality of life, without altering overall survival (OS). Despite this understanding, treatment of mRCC remains lifelong, as there has yet to be a prospective, randomized control trial to evaluate this key question. In this review, we analyze available studies in patients with mRCC on dual ICI therapy and propose considerations for early treatment discontinuation. Additionally, we discuss vital questions and the next steps to help physicians and patients navigate these challenging treatment decisions.
对于转移性肾细胞癌(mRCC)患者，双免疫检查点抑制剂(ICI)治疗的最佳持续时间尚不清楚。然而，越来越多的证据表明，部分达到完全或部分缓解的患者即使在停止治疗后也会有持久的缓解，从而延长无治疗生存期(TFS)。双ICI的TFS是靶向药物中未见的现象，有可能改善患者报告的结果和生活质量，而不会改变总生存期(OS)。尽管有这样的认识，mRCC的治疗仍然是终身的，因为还没有一个前瞻性的随机对照试验来评估这个关键问题。在这篇综述中，我们分析了mRCC患者双重ICI治疗的现有研究，并提出了早期停药的考虑。此外，我们讨论重要的问题和下一步，以帮助医生和患者导航这些具有挑战性的治疗决策。
{"title":"Optimal Duration of Therapy in Metastatic RCC: Exploring Treatment-Free Survival with Checkpoint Inhibitors","authors":"Grayce Selig, C. Hoimes, Joe Bible, D. George, M. Harrison","doi":"10.52733/kcj20n3-a1","DOIUrl":"https://doi.org/10.52733/kcj20n3-a1","url":null,"abstract":"The optimal duration of treatment for patients with metastatic renal cell carcinoma (mRCC) on dual immune checkpoint inhibitor (ICI) therapy remains unknown. However, there is evolving evidence that a portion of patients who achieve a complete or partial response will have a durable response, even after therapy discontinuation, leading to prolonged treatment-free survival (TFS). TFS with dual ICI is a phenomenon not seen with targeted agents and has the potential to improve patient reported outcomes and quality of life, without altering overall survival (OS). Despite this understanding, treatment of mRCC remains lifelong, as there has yet to be a prospective, randomized control trial to evaluate this key question. In this review, we analyze available studies in patients with mRCC on dual ICI therapy and propose considerations for early treatment discontinuation. Additionally, we discuss vital questions and the next steps to help physicians and patients navigate these challenging treatment decisions.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85158117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma 替沃扎尼加纳武单抗联合治疗肾细胞癌的最新进展
Kidney cancer journal : official journal of the Kidney Cancer Association
Pub Date : 2022-06-02 DOI: 10.52733/kcj20n2-rt
Robert Motzer, T. Choueiri, L. Albiges, R. Figlin
The treatment landscape of advanced renal cell carcinoma (aRCC) has witnessed significant benefits from the introduction of VEGF TKI/ICI (vascular endothelial growth factor receptor tyrosine kinase inhibitor/immune checkpoint inhibitor) combination in the first-line treatment. Such outcome benefits could extend to the relapsed/refractory setting with an effective, well-tolerated novel combination. Since the U.S. FDA approval of tivozanib monotherapy for the treatment of adult patients with relapsed or refractory advanced RCC following two or more prior systemic therapies,1 there is growing interest in exploring its full potential in combination with anti-PD-1 like ICI agents. In this roundtable discussion, internationally renowned cancer experts brainstorm the potential immunomodulatory capabilities of tivozanib plus nivolumab combination as first-liane and beyond settings in patients with metastatic RCC. The expert panel also explore potential data from previous and ongoing clinical trials and shared their perspectives about a tolerable safety profile and promising antitumor efficacy
在一线治疗中引入血管内皮生长因子受体酪氨酸激酶抑制剂/免疫检查点抑制剂(VEGF TKI/ICI)联合治疗晚期肾细胞癌(aRCC)的治疗前景显著。这种结果的好处可以扩展到复发/难治性的有效，耐受性良好的新组合。自从美国FDA批准替伏扎尼单药治疗既往接受两种或两种以上全身治疗的复发或难治性晚期RCC成人患者以来，人们越来越有兴趣探索其与抗pd -1样ICI药物联合的全部潜力。在这次圆桌讨论中，国际知名的癌症专家集思广益，讨论了tivozanib + nivolumab联合治疗转移性RCC患者的一线及其他治疗方案的潜在免疫调节能力。专家小组还探讨了以前和正在进行的临床试验的潜在数据，并分享了他们对可容忍的安全性和有希望的抗肿瘤功效的看法
{"title":"Recent Advances in Tivozanib plus Nivolumab Combinatorial Strategies in Renal Cell Carcinoma","authors":"Robert Motzer, T. Choueiri, L. Albiges, R. Figlin","doi":"10.52733/kcj20n2-rt","DOIUrl":"https://doi.org/10.52733/kcj20n2-rt","url":null,"abstract":"The treatment landscape of advanced renal cell carcinoma (aRCC) has witnessed significant benefits from the introduction of VEGF TKI/ICI (vascular endothelial growth factor receptor tyrosine kinase inhibitor/immune checkpoint inhibitor) combination in the first-line treatment. Such outcome benefits could extend to the relapsed/refractory setting with an effective, well-tolerated novel combination. Since the U.S. FDA approval of tivozanib monotherapy for the treatment of adult patients with relapsed or refractory advanced RCC following two or more prior systemic therapies,1 there is growing interest in exploring its full potential in combination with anti-PD-1 like ICI agents. In this roundtable discussion, internationally renowned cancer experts brainstorm the potential immunomodulatory capabilities of tivozanib plus nivolumab combination as first-liane and beyond settings in patients with metastatic RCC. The expert panel also explore potential data from previous and ongoing clinical trials and shared their perspectives about a tolerable safety profile and promising antitumor efficacy","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"104 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72968575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kidney Cancer Research Highlights from ASCO 2022 Annual Meeting. ASCO 2022年年会肾癌研究亮点
Kidney cancer journal : official journal of the Kidney Cancer Association
Pub Date : 2022-06-01
Yasser Ged, Nirmish Singla

The 2022 American Society of Clinical Oncology (ASCO) annual meeting was held June 3-7, 2022, in Chicago, Illinois. This hybrid meeting gathered international cancer experts across multidisciplinary specialties and was held both virtually and in-person. Here, we highlight key kidney cancer research updates presented at the meeting. Slides from the meeting's presentations are available on the ASCO meeting library website.

2022年美国临床肿瘤学会(ASCO)年会于2022年6月3日至7日在伊利诺伊州芝加哥市举行。这次混合会议汇集了多学科专业的国际癌症专家，并以虚拟和面对面的方式举行。在此，我们重点介绍会议上提出的关键肾癌研究进展。会议演讲的幻灯片可以在ASCO会议图书馆网站上找到。
{"title":"Kidney Cancer Research Highlights from ASCO 2022 Annual Meeting.","authors":"Yasser Ged,&nbsp;Nirmish Singla","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The 2022 American Society of Clinical Oncology (ASCO) annual meeting was held June 3-7, 2022, in Chicago, Illinois. This hybrid meeting gathered international cancer experts across multidisciplinary specialties and was held both virtually and in-person. Here, we highlight key kidney cancer research updates presented at the meeting. Slides from the meeting's presentations are available on the ASCO meeting library website.</p>","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"20 2","pages":"61-64"},"PeriodicalIF":0.0,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9725101/pdf/nihms-1822583.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10321676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GU22 ASCO - IMPORTANT ABSTRACTS Gu22 asco -重要摘要
Kidney cancer journal : official journal of the Kidney Cancer Association
Pub Date : 2022-03-16 DOI: 10.52733/kcj20n1-gu22abs
Robert Figlin
GU22 ASCO - Important Abstracts presented in the field of Kidney Cancer at ASCO Genitourinary Cancers Symposium.
GU22 ASCO -在ASCO泌尿生殖系统癌症研讨会上介绍了肾癌领域的重要摘要。
{"title":"GU22 ASCO - IMPORTANT ABSTRACTS","authors":"Robert Figlin","doi":"10.52733/kcj20n1-gu22abs","DOIUrl":"https://doi.org/10.52733/kcj20n1-gu22abs","url":null,"abstract":"GU22 ASCO - Important Abstracts presented in the field of Kidney Cancer at ASCO Genitourinary Cancers Symposium.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75110168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
20th Anniversary Issue of The Kidney Cancer Journal: Reflecting the Past, Celebrating the Present and Shaping the Future 《肾癌杂志》20周年纪念:回顾过去，庆祝现在，塑造未来
Kidney cancer journal : official journal of the Kidney Cancer Association
Pub Date : 2022-03-16 DOI: 10.52733/kcj20n1-e
Robert Figlin
Dear Colleagues, It is with a great deal of pride that we celebrate the 20th Anniversary of The Kidney Cancer Journal and its continuing success as a renowned publication in the field of kidney cancers. The Kidney Cancer Journal published its first issue in 2003, and during the last two decades, it has grown rapidly in content, audience reach, and status. The journal's 20th anniversary, therefore, deserves a review of the journey that we've been through, as well as a look into its future. It seems appropriate to use this editorial to reflect upon these achievements – including the contribution that the Kidney Cancer Journal has made to the evolution of research within the discipline and awareness.
我们非常自豪地庆祝《肾癌杂志》创刊20周年，以及它作为肾癌领域知名刊物的持续成功。《肾癌杂志》于2003年出版了第一期，在过去的二十年里，它在内容、受众范围和地位上都有了迅速的增长。因此，《华尔街日报》创刊20周年，值得我们回顾一下我们走过的历程，并展望一下它的未来。用这篇社论来反思这些成就似乎是合适的——包括《肾癌杂志》对该学科和意识的研究发展所做的贡献。
{"title":"20th Anniversary Issue of The Kidney Cancer Journal: Reflecting the Past, Celebrating the Present and Shaping the Future","authors":"Robert Figlin","doi":"10.52733/kcj20n1-e","DOIUrl":"https://doi.org/10.52733/kcj20n1-e","url":null,"abstract":"Dear Colleagues, It is with a great deal of pride that we celebrate the 20th Anniversary of The Kidney Cancer Journal and its continuing success as a renowned publication in the field of kidney cancers. The Kidney Cancer Journal published its first issue in 2003, and during the last two decades, it has grown rapidly in content, audience reach, and status. The journal's 20th anniversary, therefore, deserves a review of the journey that we've been through, as well as a look into its future. It seems appropriate to use this editorial to reflect upon these achievements – including the contribution that the Kidney Cancer Journal has made to the evolution of research within the discipline and awareness.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"55 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80532657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A 20-Year Retrospective of Kidney Cancer Journal: 2003-2022 肾癌20年回顾性研究杂志:2003-2022
Kidney cancer journal : official journal of the Kidney Cancer Association
Pub Date : 2022-03-16 DOI: 10.52733/kcj20n1-20yr
S. Pazhanisamy
These 20 years of the Kidney Cancer Journal’s journey encapsulate the most dramatic advances ever achieved in the management of RCC. This Q&A with Editor-in-Chief Robert A. Figlin, MD, reflects on the last two decades of the journey, and significant milestones in the evolution of strategies and optimized outcomes.
《肾癌杂志》这20年的历程概括了在肾细胞癌管理方面取得的最引人注目的进展。本文与主编Robert A. Figlin博士进行了问答，回顾了过去二十年的历程，以及战略发展和优化结果的重要里程碑。
{"title":"A 20-Year Retrospective of Kidney Cancer Journal: 2003-2022","authors":"S. Pazhanisamy","doi":"10.52733/kcj20n1-20yr","DOIUrl":"https://doi.org/10.52733/kcj20n1-20yr","url":null,"abstract":"These 20 years of the Kidney Cancer Journal’s journey encapsulate the most dramatic advances ever achieved in the management of RCC. This Q&A with Editor-in-Chief Robert A. Figlin, MD, reflects on the last two decades of the journey, and significant milestones in the evolution of strategies and optimized outcomes.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"629 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79011171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ASCO GU22 – Kidney Cancer Highlights ASCO GU22 -肾癌亮点
Kidney cancer journal : official journal of the Kidney Cancer Association
Pub Date : 2022-03-16 DOI: 10.52733/kcj20n1-gu2
J. Graham
The 2022 ASCO Genitourinary Cancers Symposium took place in San Francisco between February 17-19th. As always, the scientific program contained several exciting abstracts with a focus on prostate cancer, bladder cancer, and kidney cancer. Here we will highlight key abstracts related to kidney cancer/renal cell carcinoma presented at this year’s symposium.
2022年ASCO泌尿生殖系统癌症研讨会于2月17日至19日在旧金山举行。一如既往，科学计划包含了一些令人兴奋的摘要，重点是前列腺癌、膀胱癌和肾癌。在这里，我们将重点介绍在今年的研讨会上发表的与肾癌/肾细胞癌相关的关键摘要。
{"title":"ASCO GU22 – Kidney Cancer Highlights","authors":"J. Graham","doi":"10.52733/kcj20n1-gu2","DOIUrl":"https://doi.org/10.52733/kcj20n1-gu2","url":null,"abstract":"The 2022 ASCO Genitourinary Cancers Symposium took place in San Francisco between February 17-19th. As always, the scientific program contained several exciting abstracts with a focus on prostate cancer, bladder cancer, and kidney cancer. Here we will highlight key abstracts related to kidney cancer/renal cell carcinoma presented at this year’s symposium.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"83 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79795979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Moving Beyond BMI – Developments in Body Composition and Muscle Measurement in Renal Cell Carcinoma 超越BMI -肾细胞癌中身体成分和肌肉测量的发展
Kidney cancer journal : official journal of the Kidney Cancer Association
Pub Date : 2022-03-16 DOI: 10.52733/kcj20n1-r1
H. Dzimitrowicz, J. Infield, Fides Regina Schwartz, Rajan Gupta, Michael Harrison
Body composition, namely the distribution and quantification of muscle and adipose tissue, are of increasing interest as potential prognostic indicators in patients with renal cell carcinoma (RCC). Herein, we review the available literature examining body composition in relation to outcomes for patients with RCC, methodology used to quantify muscle and adipose tissue using cross-sectional imaging, and future directions for translation of these findings into clinical care.
身体组成，即肌肉和脂肪组织的分布和定量，作为肾细胞癌(RCC)患者的潜在预后指标越来越受到关注。在此，我们回顾了现有的研究RCC患者身体成分与预后的关系的文献，使用横断面成像量化肌肉和脂肪组织的方法，以及将这些发现转化为临床护理的未来方向。
{"title":"Moving Beyond BMI – Developments in Body Composition and Muscle Measurement in Renal Cell Carcinoma","authors":"H. Dzimitrowicz, J. Infield, Fides Regina Schwartz, Rajan Gupta, Michael Harrison","doi":"10.52733/kcj20n1-r1","DOIUrl":"https://doi.org/10.52733/kcj20n1-r1","url":null,"abstract":"Body composition, namely the distribution and quantification of muscle and adipose tissue, are of increasing interest as potential prognostic indicators in patients with renal cell carcinoma (RCC). Herein, we review the available literature examining body composition in relation to outcomes for patients with RCC, methodology used to quantify muscle and adipose tissue using cross-sectional imaging, and future directions for translation of these findings into clinical care.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77708790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances in BEMPEG (NKTR-214) plus NIVOLUMAB Combination Strategies in Advanced Renal Cell Carcinoma BEMPEG (NKTR-214)联合NIVOLUMAB治疗晚期肾细胞癌的最新进展
Kidney cancer journal : official journal of the Kidney Cancer Association
Pub Date : 2022-03-16 DOI: 10.52733/kcj20n1-rt
N. Tannir, A. Siefker-Radtke, R. Figlin
In this roundtable discussion, renowned cancer experts analyze the potential immunomodulatory capabilities of bempegaldesleukin (BEMPEG; NKTR- 214) in combination with an immune checkpoint inhibitor (CPI; anti-PD-1) in the therapeutic landscape of advanced renal cell carcinoma (aRCC) and other genitourinary cancers. The expert panel also shared their perspectives regarding the latest data from ongoing clinical trials which continue to show an encouraging efficacy and safety, risk/benefit of BEMPEG plus CPI combination.
在本次圆桌会议讨论中，知名癌症专家分析了本培galdesleukin (BEMPEG;NKTR- 214)与免疫检查点抑制剂(CPI;抗pd -1)在晚期肾细胞癌(aRCC)和其他泌尿生殖系统癌症的治疗前景。专家小组还分享了他们对正在进行的临床试验的最新数据的看法，这些数据继续显示BEMPEG和CPI组合的有效性和安全性，风险/收益令人鼓舞。
{"title":"Recent Advances in BEMPEG (NKTR-214) plus NIVOLUMAB Combination Strategies in Advanced Renal Cell Carcinoma","authors":"N. Tannir, A. Siefker-Radtke, R. Figlin","doi":"10.52733/kcj20n1-rt","DOIUrl":"https://doi.org/10.52733/kcj20n1-rt","url":null,"abstract":"In this roundtable discussion, renowned cancer experts analyze the potential immunomodulatory capabilities of bempegaldesleukin (BEMPEG; NKTR- 214) in combination with an immune checkpoint inhibitor (CPI; anti-PD-1) in the therapeutic landscape of advanced renal cell carcinoma (aRCC) and other genitourinary cancers. The expert panel also shared their perspectives regarding the latest data from ongoing clinical trials which continue to show an encouraging efficacy and safety, risk/benefit of BEMPEG plus CPI combination.","PeriodicalId":74040,"journal":{"name":"Kidney cancer journal : official journal of the Kidney Cancer Association","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-03-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78630561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
类型
全部 化学•材料 生命科学 医学 物理 工程技术 环境•农林 材料科学 地球科学 法学 管理学 化学 环境科学与生态学 计算机科学 教育学 经济学 农林科学 人文科学 生物学 数学 物理与天体物理 心理学 综合性期刊 其他 工业工程 理学 历史学 农学 文学 信息工程
数据库
全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley
期刊
Kidney cancer journal : official journal of the Kidney Cancer Association
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们：info@booksci.cn
Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1